Drugs / Delafloxacin
Delafloxacin
also known as
ABT-492 · Baxdela · Delafloxacine · Delafloxacino · Quofenix · RX-3341 · WQ-3034 · WQ-3034 AND ABT-492
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Quofenix | — | 2019-12-16 | europa.eu ↗ |
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06612255 | Jun → Sep 2024 | — | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03534622 | Apr → Jul 2018 | pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02505997 | Jun → Jul 2015 | — | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02245243 | Sep 2014 → Feb 2015 | — | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01283581 | Jan → Nov 2011 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00719810 | Jun → Oct 2008 | skin disease caused by bacterial infection, skin infection, staphylococcal infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04042077 | Sep 2019 → Oct 2020 | — | Menarini Group | Terminated | No outcome recorded |
| Phase 3 | NCT02679573 | Dec 2016 → Jul 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01984684 | May 2014 → Dec 2015 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02015637 | Jan → Nov 2014 | gonorrhea | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01811732 | Apr 2013 → Jul 2014 | skin disease caused by bacterial infection | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delafloxacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02679573 ↗ |
| Known as | ABT-492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | Baxdela | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | Delafloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | Delafloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | Quofenix | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | RX-3341 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | WQ-3034 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Known as | WQ-3034 AND ABT-492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105637 ↗ |
| Modality | Small molecule | “RX-3341 (delafloxacin), a fluoroquinolone” NCT00719810 ↗ |
| Route | Intravenous | “delafloxacin 300mg intravenous (IV) every 12h” PMID 25448332 ↗ Oct 2014 |